Ryvu Therapeutics S.A. announced the appointment of Hendrik Nogai, M.D. to the role of Chief Medical Officer effective February 1, 2022. Dr. Nogai will lead medical, clinical, and regulatory functions to support and guide the development of the company's pipeline. Dr. Nogai is a board-certified medical doctor in Hematology/Oncology as well as in Internal Medicine, with almost 10 years of experience in patient care and basic research in different academic settings, including Charit University Medicine Berlin, University Hospital Grosshadern in Munich, and Zentralklinikum Augsburg.

Besides his clinical expertise, Dr. Nogai brings 17 years of industry experience including business consulting at Mercer Management Consulting/Oliver Wyman, Medical Advisor role at Nordic Biotech Capital ApS, and positions of increasing responsibility at Bayer AG, with his most recent role of Vice President, Global Development Leader NTRK program.